A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Muscular Dystrophies

Interventions

DRUG

Drisapersen

Subcutaneous and Intravenous